imperial chemical industries plc largest chemical company united kingdom will expand its specialty chemicals and drug businesses this year and better its 1986 results said chairman elect denys henderson expect shift company higher value added businesses and continue broaden base henderson told reporters informal meeting ici today announced formation new drug company ici pharma which with its stuart pharmaceuticals unit said will double its current pharmaceutical sales billion dlrs 1990 henderson said pharmaceutical business gets lost way glaxo glaxo holdings plc does not ici pharmaceutical division second largest drug maker behind glaxo last year drug sales were about pct its worldwide drug sales billion dlrs which turn brought pct its total profits estimated 1990 ici pharmaceutical division would account for about pct total company profits drug division far and away brings highest rate return said clements finance director ici was also meeting henderson said new drug concern would basically act second sales force double exposure its drugs doctors ici will hire 145 new salespeople october henderson said major new products company pipeline expected each bring sales over 200 mln dlrs annually were statil treatment for diabetic complications zoladex treatment for advanced prostate cancer and carwin treatment for mild moderate congestive heart failure henderson said food and drug administration approval market statil and zoladex both under joint licensing agreements with merck and inc not expected until about 1989 ici expects file for permission market carwin later this year henderson said company 1987 results would top 1986 income 888 mln dlrs dlrs per adr sales billion dlrs but declined specify how much henderson said 1987 results would boosted glidden paints which ici bought last november for 580 mln dlrs from unit hanson industries inc henderson also said ici has about nine billion dlrs available for acquisitions last year company made acquisitions largest being glidden said more acquisitions may made this year but ruled out acquisition pharmaceutical concern expensive henderson said his new role chairman effective april when takes over from sir john harvey jones will retire biggest challenge ahead lay continuing earnings momentum ici has established over past few years after restructuring and selling off unprofitable businesses reuter 